Paid Clinical Trials in Michigan

Browse 97 Paid Studies Michigan Across 839 Cities

48 Phase 3 Trial ยท 5992 Paid Studies Michigan Clinics

Clinical TrialsPaid Clinical Trials in Michigan
Reviewed by Michael Gill, B. Sc.
10 Paid Studies Michigan Near Me
Top Cities for Paid Studies Michigan
Image of Anchorage in Alaska.
Anchorage
126Active Trials
Katmai Oncology GroupTop Active Site
Image of Los Angeles in California.
Los Angeles
79Active Trials
Kaiser Permanente Los Angeles Medical CenterTop Active Site
Paid Studies Michigan by Phase of Trial
N/A Paid Studies Michigan
11Active Paid Studies Michigan
11Number of Unique Treatments
457Number of Active Locations
Reciprocity (randomized weekly, 1 of 4 options)Serum Tumor Marker directed disease monitoringOviTex Reinforced Tissue MatrixIntensive Medical Management - no CEAScreening (biospecimen collection)Intervention-EDI and health coachinga bipolar percutaneous intramuscular electromyography electrodeModel 400 aortic valve bioprosthesis
Most Recent Paid Studies Michigan
Clinical Trial
Began Recruiting Date
Phase
Arm C (rescue levocarnitine) for Acute Lymphoblastic Leukemia
8/14/2023
Phase 3
Step II Arm II (polatuzumab vedotin) for Diffuse Large B-Cell Lymphoma
6/12/2023
Phase 2
Arm B (ABVD, brentuximab vedotin, nivolumab) for Hodgkin's Lymphoma
4/28/2023
Phase 3
Arm A: Dose 1 for Atopic Dermatitis
4/20/2023
Phase 3
ARM B (ramucirumab, pembrolizumab) for Non-Small Cell Lung Cancer
3/14/2023
Phase 3

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 19th, 2021

Last Reviewed: August 10th, 2023

References1 Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. https://pubmed.ncbi.nlm.nih.gov/344733432 Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9:CD013825. doi: 10.1002/14651858.CD013825.pub2. Review. https://pubmed.ncbi.nlm.nih.gov/344733433 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038. https://pubmed.ncbi.nlm.nih.gov/321710764 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum In: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038. https://pubmed.ncbi.nlm.nih.gov/321710765 Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. Review. https://pubmed.ncbi.nlm.nih.gov/314019036 Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. https://pubmed.ncbi.nlm.nih.gov/314019037 Flumignan RL, Tinรดco JDS, Pascoal PI, Areias LL, Cossi MS, Fernandes MI, Costa IK, Souza L, Matar CF, Tendal B, Trevisani VF, Atallah รN, Nakano LC. Prophylactic anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2020 Oct 2;10:CD013739. doi: 10.1002/14651858.CD013739. https://pubmed.ncbi.nlm.nih.gov/335027738 Flumignan RL, Tinรดco JDS, Pascoal PI, Areias LL, Cossi MS, Fernandes MI, Costa IK, Souza L, Matar CF, Tendal B, Trevisani VF, Atallah รN, Nakano LC. Prophylactic anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2020 Oct 2;10:CD013739. doi: 10.1002/14651858.CD013739. Update in: Cochrane Database Syst Rev. 2022 Mar 4;3:CD013739. https://pubmed.ncbi.nlm.nih.gov/335027739 Flumignan RL, Tinoco JDS, Pascoal PI, Areias LL, Cossi MS, Fernandes MI, Costa IK, Souza L, Matar CF, Tendal B, Trevisani VF, Atallah AN, Nakano LC. Prophylactic anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2020 Oct 2;10(10):CD013739. doi: 10.1002/14651858.CD013739. https://pubmed.ncbi.nlm.nih.gov/3350277310 Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10. https://pubmed.ncbi.nlm.nih.gov/32291094
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top